CHMP recommends label update for Esbriet® in idiopathic pulmonary fibrosis
Roche announced Esbriet® (pirfenidone) has received a positive opinion from the CHMP for an update to its European prescribing information, strengthening the efficacy claims and supporting the well-established safety profile based on the additional data from the phase III ASCEND trial. October 24, 2014